Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Profession Business and Innovation, Cataract, Glaucoma, Retina

Business in Brief

Credit: Image Sourced from

DORC has received 510(k) market clearance for its first surgical system approved for sub- retinal injections, EVA NEXUS, in the US. The company also showed the next generation of its two-dimensional cutter, TDC VELOCE, at ASRS. Link

Rayner has announced direct entry into the French cataract and refractive market, with ophthalmologists in France now gaining access to Rayner’s portfolio of RayOne and Sulcoflex IOLs, the AEON family of eye drops, and the RayONE digital platform for collecting Patient Reported Outcomes. Link

REGENXBIO has just opened its state-of-the-art, $65 million Manufacturing Innovation Center – gene therapy manufacturing facility – in Montgomery County, Maryland, US. Link

Bausch + Lomb is releasing an efficiency-enhancing upgrade for the Stellaris Elite vision enhancement system; the upgrade is first in a series that will include an increase to the maximum vacuum setting and an enhancement to the removable caps in the trocar/cannula system. Link

Ashvattha Therapeutics has presented data from a Phase I study of a self-administered anti- VEGF therapy for DME. D-4517.2 has shown potential as a therapy addressing DME patients’ treatment burden. Link

Samsara Vision has completed first US surgeries using its SING IMT (Smaller-Incision New- Generation Implantable Miniature Telescope) as part of the CONCERTO study evaluating safety and efficacy of the telescope in patients with late-stage AMD. Link

Research from BioTissue’s co-founder and CTO, Scheffer C.G. Tseng, has been recognized as the most cited lab investigation in the history of corneal research. Tseng’s work on the potential of the amniotic membrane in ophthalmology has received over 1,300 citations to date. Link

Studies featuring Notal Vision’s home-based, patient-operated OCT for monitoring wet AMD progression have shown the device’s efficacy and feasibility. Link

Oculis has announced the start of enrollment into its Phase III OPTIMIZE trial of OCS-01 for treating inflammation and pain after cataract surgery. Also, Phase III DIAMOND trial is investigating OCS-01 for DME treatment. Link

Harrow Health has announced the US launch of IOPIDINE 1%, and MAXITROL, with these medications now commercially available, and plans to commercialize MOXEZA 0.5% at a later date. Link

Occuity, developer of the PM1 Pachymeter that helps detect glaucoma, has opened a new funding round for new projects, including a handheld, non-contact axial length meter, which could aid myopia measurements in children. Link

Heidelberg Engineering has added new features to its anterior segment platform, ANTERION, in European markets. New and existing customers will now have access to epithelial thickness measurements, intuitive visualization to assess corneal ectasia, and automatic anterior chamber measurements (via a software update for existing users). Link

Ace Vision Group, an ophthalmic company developing innovative touchless lasers to patients with age-related vision loss, has appointed Elizabeth Yeu as its Chief Strategic Advisor. Link

Reichert Technologies celebrated the 100th anniversary of the first phoropter. The refracting instrument, released in 1922, has revolutionized eye care. The celebrations were held earlier this month at the company’s Depew, New York, US location. Link

Rayner has entered into a partnership with Belgian surgical instrument manufacturer, HASA Optix, and acquired a stake in the business. HASA instruments will be available from Rayner in selected countries, including the US, later in 2022. Link

Quantel Medical has launched its Nd:YAG laser, Capsulo, a fully integrated, easy to use and highly versatile laser platform, enabling efficient and accurate capsulotomy and iridotomy treatments. Link

LENSAR’s ALLY Adaptive Cataract Treatment System has received US FDA clearance this week. ALLY enables a completely sterile FLACS procedure in any OR or surgical suite. Link

Aurion Biotech, a company working on a cell therapy to treat corneal edema secondary to endothelial dysfunction, has appointed Michael Goldstein as its President and Chief Medical Officer. Goldstein’s previous appointments include Ocular Therapeutix, Applied Genetic Technologies Corp, and Eleven Biotherapeutics. Link

iSTAR presented two-year safety and efficacy results in a meta-analysis of its STAR-I, STAR-II and STAR-III clinical trials for MINIject, a supraciliary MIGS device. The two-year results showed efficacy and favorable safety outcomes in patients with primary open-angle glaucoma. Link

Coave Therapeutics and ABL have announced a strategic collaboration to develop and manufacture an AAV-based gene therapy. Link 

ZEISS is celebrating more than 500,000 planned US-based surgeries using its VERACITY Surgical platform, which increases workflow efficiency by integrating patient data from EHRs and diagnostic hardware for automated surgical planning accessed from any location. Link

Biogen and Samsung Bioepis’ BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), has been launched in the US. Priced 40 percent lower than LUCENTIS, BYOOVIZ provides an equally effective and more affordable treatment option to patients suffering from retinal disorders. Link

The FDA has approved Novartis’ BEOVU (brolucizumab-dbll) 6 mg for the treatment of DME. It is the second FDA-approved indication for BEOVU, the first being the treatment of wet AMD in 2019. Link

Horizon Therapeutics has shared data from the Phase III trial of UPLIZNA, a new NMOSD treatment. Data from 142 subjects show the treatment’s effectiveness among patients of various genetic make-ups. Link

Sight Sciences has announced 12-month outcomes in the GEMINI study, which show that 360° canaloplasty and 180° trabeculotomy performed with the company’s OMNI Surgical System at the time of cataract surgery significantly reduces unmedicated mean diurnal IOP and medication use for at least 12 months. Link

Oertli Instrumente has acquired Swiss distributor Domedics, which has given the company direct access to Swiss, Austrian, and German markets. Now, Domedics has turned into Oertli Ophthalmedic Schweiz, a subsidiary of the global Oertli brand. Link

Haag-Streit has launched its fourth Slit Lamp Competition, inviting eyecare professionals across the world to showcase their slit lamp imaging skills. Criteria include image quality, technical execution, and disease interest, with prizes being awarded for the first three places. The competition closes on August 12. Link

Research supporting cataract surgeons and other eye professionals in helping patients prepare for surgery recommends prescribing a pre-surgical preparation kit, such as Bruder Healthcare’s Sx Pre-Surgical Patient Prep Kit, which helps patients combat fear and anxiety while giving them agency and autonomy. Link

Dopavision, a company developing digital therapeutics for childhood myopia, has appointed Mark S. Wuttke as its CEO. Wuttke previously worked on developing and commercializing ophthalmic products at Novartis. Link

Lumenis, an energy-based medical device company developing eye care applications, has announced that its light-based treatment of dry eye, OptiLight, has won the 2022 MedTech Breakthrough Award for Best New Technology Solution for Ophthalmology. Link

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Aleksandra Jones

Editor of The Ophthalmologist

Having edited several technical publications over the last decade, I crossed paths with quite a few of Texere's current team members, and I only ever heard them sing the company's praises. When an opportunity arose to join Texere, I jumped at the chance! With a background in literature, I love the company's ethos of producing genuinely engaging content, and the fact that it is so well received by our readers makes it even more rewarding.

Related Product Profile
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine